<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444859</url>
  </required_header>
  <id_info>
    <org_study_id>110725-SUS-NIP-GIS-RA</org_study_id>
    <nct_id>NCT01444859</nct_id>
  </id_info>
  <brief_title>Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms</brief_title>
  <official_title>Effect of Trenev Trio®/Healthy Trinity® in Otherwise Healthy Adults With Recurrent Gastrointestinal Symptoms: a Double-blind, Randomized, Placebo-controlled, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The National Institute of Probiotics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sprim Advanced Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to compare safety and effectiveness of 10-week supplementation with Trenev&#xD;
      Trio®/Healthy Trinity® vs. placebo in otherwise healthy subjects with recurrent&#xD;
      gastrointestinal symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, parallel group trial comparing&#xD;
      the safety and effectiveness of supplementation with Trenev Trio®/Healthy Trinity® vs.&#xD;
      placebo in otherwise healthy subjects with recurrent gastrointestinal symptoms. Subjects will&#xD;
      be recruited and, following successful completion of a 2-week run-in period, will be&#xD;
      randomized to Trenev Trio®/Healthy Trinity® or placebo and will consume their assigned study&#xD;
      product daily for 10 weeks. The study endpoints of this trial include relief of overall&#xD;
      gastrointestinal symptoms, acid indigestion, abdominal cramping, constipation, diarrhea, gas,&#xD;
      and bloating as well as product safety over the 10-week supplementation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean total Gastrointestinal Symptom Rating Scale (GSRS) score</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Quality of Life Index (GIQLI) total score</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale subscores</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gas severity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloating severity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acid indigestion severity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal cramping severity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency (measured with Bristol Stool Form Scale)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication use</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event severity</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Recurrent Gastrointestinal Symptoms</condition>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 subjects allocated to daily placebo capsule for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trenev Trio®/Healthy Trinity®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trenev Trio®/Healthy Trinity®</intervention_name>
    <description>Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)</description>
    <arm_group_label>Trenev Trio®/Healthy Trinity®</arm_group_label>
    <other_name>Probiotic</other_name>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily placebo for 10 weeks</description>
    <arm_group_label>Placebo capsule</arm_group_label>
    <other_name>Inactive</other_name>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Body mass index between 18.5 through 39.9 kg/m2&#xD;
&#xD;
          3. At least three symptoms rated between 4 to 6 in severity (moderate to severe&#xD;
             discomfort) on a 1 to 7 scale, one of which must be acid indigestion as determined by&#xD;
             the &quot;Reflux Syndrome&quot; score&#xD;
&#xD;
          4. Self-reported &quot;acid indigestion&quot; symptoms (including pain/discomfort beneath the&#xD;
             breastbone, bitter fluid in the mouth, or bloating/nausea after eating) at least 3&#xD;
             times per week over the previous 4 weeks&#xD;
&#xD;
          5. Agree to use contraception throughout study period, unless postmenopausal or&#xD;
             surgically sterile (females only)&#xD;
&#xD;
          6. Able to understand and voluntarily consent to the study and understand it's nature and&#xD;
             purpose including potential risks, and side effects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any GSRS symptom rated a 7 in severity (very severe discomfort) on a 1 to 7 scale&#xD;
&#xD;
          2. Diagnosed gastrointestinal disease/complication or functional bowel disorder (e.g.&#xD;
             IBS, functional constipation, IBD, ulcer, etc.) based on physical examination or&#xD;
             documented medical history that, in the investigator's opinion, may affect subject&#xD;
             safety or confound the evaluation of the study endpoints&#xD;
&#xD;
          3. Any non-gastrointestinal disease/complication that, in the investigator's opinion, may&#xD;
             affect subject safety or confound the evaluation of the study endpoints&#xD;
&#xD;
          4. Regular (&gt;3 days per week) prescription medication use for any gastrointestinal&#xD;
             disease/condition&#xD;
&#xD;
          5. Recent (&lt;6 months) abdominal surgery for any reason&#xD;
&#xD;
          6. Immunodeficiency&#xD;
&#xD;
          7. Recent change in anti-psychotic medication within the previous 3 months&#xD;
&#xD;
          8. Systemic steroid use within the prior month, excluding regular use of asthma&#xD;
             medication&#xD;
&#xD;
          9. Pregnant female or breastfeeding&#xD;
&#xD;
         10. Eating disorder&#xD;
&#xD;
         11. Recent (within 2 weeks) antibiotic administration&#xD;
&#xD;
         12. History of alcohol, drug, or medication abuse&#xD;
&#xD;
         13. Daily consumption of probiotics, fermented milk, and/or yogurt&#xD;
&#xD;
         14. Known allergies to any substance in the study product&#xD;
&#xD;
         15. Participation in another study with any investigational product within 30 days of&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duane Wombolt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Associates of Tidewater</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Across America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sinitsa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Across America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Stacey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diablo Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lydie Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Axis Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JoAnn Hattner, MPH, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sprim ALS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sprim ALS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>West Lawn</city>
        <state>Pennsylvania</state>
        <zip>19609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

